Biostem Technologies, Inc. (NASDAQ:BSEM – Free Report) – HC Wainwright increased their Q3 2026 earnings per share estimates for Biostem Technologies in a research note issued on Monday, August 24th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.43) for the quarter, up from their prior forecast of ($0.46). The consensus estimate for Biostem Technologies’ current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Biostem Technologies’ Q4 2026 earnings at ($0.45) EPS, FY2026 earnings at ($1.90) EPS, Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.31) EPS, Q3 2027 earnings at ($0.20) EPS, Q4 2027 earnings at ($0.15) EPS, FY2027 earnings at ($1.04) EPS, FY2028 earnings at ($0.09) EPS, FY2029 earnings at $0.28 EPS and FY2030 earnings at $0.58 EPS.
Separately, Weiss Ratings started coverage on shares of Biostem Technologies in a report on Wednesday, August 19th. They issued a “sell (d-)” rating for the company. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Biostem Technologies presently has an average rating of “Sell”.
Biostem Technologies Stock Up 5.2%
NASDAQ:BSEM opened at $3.85 on Friday. The firm’s fifty day simple moving average is $3.59 and its 200 day simple moving average is $4.47. The stock has a market cap of $68.72 million, a P/E ratio of -2.40 and a beta of 0.11. Biostem Technologies has a twelve month low of $2.25 and a twelve month high of $8.40.
About Biostem Technologies
BioStem Technologies, Inc (NASDAQ: BSEM) is a biotechnology company focused on regenerative medicine and biologic tissue products. Through its operating businesses, the company develops, manufactures and distributes human tissue allografts intended to support wound care, surgical procedures and other regenerative applications.
Its product portfolio includes placental-tissue-based products, including amniotic membrane and related graft technologies. These products are designed for use by health-care professionals in applications such as wound management and tissue repair.
See Also
- Five stocks we like better than Biostem Technologies
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Biostem Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostem Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
